Registration number: 11730711

Sussex Urology Limited

Contents

Company Information	1
Accountants' Report	2
Balance Sheet	3
Statement of Changes in Equity	4
Notes to the Unaudited Financial Statements	5 to 8

Sussex Urology Limited

Company Information

Director

Dr R J Frymann

Registered office

Wellesley House 204 London Road Waterlooville Hampshire PO7 7AN

Accountants

MMO Limited Wellesley House 204 London Road Waterlooville Hampshire PO7 7AN

Chartered Accountants' Report to the Director on the Preparation of the Unaudited Statutory Accounts of
Sussex Urology Limited
for the Year Ended 31 March 2025

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the accounts of Sussex Urology Limited for the year ended 31 March 2025 as set out on pages 3 to 8 from the company's accounting records and from information and explanations you have given us.

As a practising member firm of the Institute of Chartered Accountants in England and Wales (ICAEW), we are subject to its ethical and other professional requirements which are detailed at
http://www.icaew.com/regulation.

This report is made solely to the Board of Directors of Sussex Urology Limited, as a body, in accordance with the terms of our engagement letter. Our work has been undertaken solely to prepare for your approval the accounts of Sussex Urology Limited and state those matters that we have agreed to state to the Board of Directors of Sussex Urology Limited, as a body, in this report in accordance with ICAEW Technical Release 07/16 AAF. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Sussex Urology Limited and its Board of Directors as a body for our work or for this report.

It is your duty to ensure that Sussex Urology Limited has kept adequate accounting records and to prepare statutory accounts that give a true and fair view of the assets, liabilities, financial position and profit of Sussex Urology Limited. You consider that Sussex Urology Limited is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or a review of the accounts of Sussex Urology Limited. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory accounts.

......................................

MMO Limited
Wellesley House
204 London Road
Waterlooville
Hampshire
PO7 7AN

22 December 2025

Sussex Urology Limited

(Registration number: 11730711)
Balance Sheet as at 31 March 2025

	Note	2025 £	2024 £
Current assets
Debtors	5	75,192	95,672
Other financial assets	4	421,741	329,420
Cash at bank and in hand		27,049	10,898
		523,982	435,990
Creditors: Amounts falling due within one year	6	(28,617)	(29,362)
Total assets less current liabilities		495,365	406,628
Provisions for liabilities		(8,427)	-
Net assets		486,938	406,628
Capital and reserves
Called up share capital	7	140	130
Other reserves		25,281	35,366
Retained earnings		461,517	371,132
Shareholders' funds		486,938	406,628

For the financial year ending 31 March 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

•	The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and
•	The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the director has not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the director on 22 December 2025
 

......................................... Dr R J Frymann Director

Sussex Urology Limited

Statement of Changes in Equity for the Year Ended 31 March 2025

	Share capital £	Other reserves £	Retained earnings £	Total £
At 1 April 2024	130	35,366	371,132	406,628
Profit for the year	-	-	90,600	90,600
Other comprehensive income	-	(10,085)	10,085	-
Total comprehensive income	-	(10,085)	100,685	90,600
Dividends	-	-	(10,300)	(10,300)
New share capital subscribed	10	-	-	10
At 31 March 2025	140	25,281	461,517	486,938

	Share capital £	Other reserves £	Retained earnings £	Total £
At 1 April 2023	130	1,139	284,482	285,751
Profit for the year	-	-	126,877	126,877
Other comprehensive income	-	34,227	(34,227)	-
Total comprehensive income	-	34,227	92,650	126,877
Dividends	-	-	(6,000)	(6,000)
At 31 March 2024	130	35,366	371,132	406,628

Sussex Urology Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2025

1	General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
Wellesley House
204 London Road
Waterlooville
Hampshire
PO7 7AN
England

2	Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

All figures are presented in British Sterling, which is the functional currency of the company, and are rounded to the nearest £1.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.

The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

Tax

The tax expense for the period comprises current and deferred tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

Sussex Urology Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2025

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Deferred tax is recognised in respect of all timing differences between taxable profits and profits reported in the financial statements.

Unrelieved tax losses and other deferred tax assets are recognised when it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference.

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Dividends

Dividend distribution to the company’s shareholders is recognised as a liability in the financial statements in the reporting period in which the dividends are declared.

3	Staff numbers

The average number of persons employed by the company (including the director) during the year, was 1 (2024 - 1).

Sussex Urology Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2025

4	Other financial assets (current and non-current)

	Financial assets at fair value through profit and loss £	Total £
Current financial assets
Cost or valuation
At 1 April 2024	329,420	329,420
Additions	93,913	93,913
Disposals	(1,592)	(1,592)
At 31 March 2025	421,741	421,741
Impairment
Carrying amount
At 31 March 2025	421,741	421,741

5

Debtors

Current	2025 £	2024 £
Trade debtors	49,195	50,820
Other debtors	25,997	44,852
	75,192	95,672

6

Creditors

Creditors: amounts falling due within one year

	2025 £	2024 £
Due within one year
Taxation and social security	28,617	29,362

Sussex Urology Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2025

7	Share capital

Allotted, called up and fully paid shares

	2025		2024
	No.	£	No.	£
Ordinary shares of £1 each	100	100	100	100
Ordinary A shares of £1 each	10	10	10	10
Ordinary B shares of £1 each	10	10	10	10
Ordinary C shares of £1 each	10	10	10	10
Ordinary D shares of £1 (2024 - £0) each	10	10	-	-
	140	140	130	130

8	Related party transactions

Transactions with the director

2025	At 1 April 2024 £	Repayments by director £	Other payments made to company by director £	At 31 March 2025 £
Dr R J Frymann
Undated, unsecured and interest free directors loan account which is repayable on demand.	44,853	(44,853)	25,998	25,998

2024	At 1 April 2023 £	Repayments by director £	Other payments made to company by director £	At 31 March 2024 £
Dr R J Frymann
Undated, unsecured and interest free directors loan account which is repayable on demand.	12,819	(12,819)	44,853	44,853